May 21st, 2021

Enantia is attending the current edition of CPhI Discover taking place online from the 17th to the 28th  of May.

We will be glad to meet you to discuss more about our Process Chemistry services, including route scouting, CMC support and scale up with our new kilo lab facilities. We also offer Medicinal Chemistry programs from hit finding to lead optimization, aside from other support activities.

Contact us also for our Solid Form Development services to optimize the properties of your candidates, improving their IP or to use our pioneering cocrystallization technology for an easy and scalable purification of complex crudes or natural extracts.

Additionally, we count with a Solid Form Analysis department for a detailed understanding of the solid phase in the development and manufacturing of APIs and fine chemicals.

Finally, we also offer pharmaceutical grade synthetic GMP CBD to be used in your clinical development programs.

You can find us during the CPhI as exhibitors and the rest of the year at info@enantia.com

March 18th, 2021

Enantia is a speaker sponsor for the “Synthesis in Drug Discovery and Development” symposium which will be held by the Royal Society of Chemistry on the 22^nd and 23^rd of March.

This event will focus in innovative synthesis facilitating candidate discovery and overcoming the challenges of their scale up. These activities are carried out by Enantia in its Medicinal Chemistry and Process Chemistry departments respectively.

If you are interested in the chemical development of your candidates to optimize their activity, selectivity or toxicologic profile (among other properties) contact us to know more about our offer in Hit finding, H2L and LO programs.

Once a candidate is selected to be moved forward in the drug discovery process, one of Enantia’s main activities is the development of scalable routes of synthesis according to our clients’ requirements for a suitable scale up.

Contact us if you would like more information about any of our services.

December 14th, 2020

We would like to wish a happy holiday to everyone who has placed their trust in Enantia during this year marked by the Covid-19 pandemic.

Thank you to all our customers, suppliers and employees, whose hard work has been essential in such a challenging year.

We wish you a safe and merry Christmas and a happy and prosperous 2021.

Enantia supports an environmental-friendly paper-free holiday season.

November 10th, 2020

The French Ministry of Higher Education, Research and Innovation has granted Enantia with the Crédit d’Impôt Recherche (CIR) for the years 2020, 2021 and 2022.

The Crédit d’Impôt Recherche is a measure to support the research and development activities of French companies that have expenses in research and experimental development, who can benefit from the CIR by deducting them from their taxes under certain conditions.

This is great news for our French customers, especially those with a strong R&D activity like pharmaceutical companies, biotech, CDMOs and CMOs, that can now benefit from our CIR accreditation in all our services, which include medicinal chemistry, chemical development, solid state development and solid form analysis.

You can check our CIR accreditation here.

October 26^th, 2020

The Journal of Medicinal Chemistry has recently reported the results obtained in our Lead Optimisation collaboration with Esteve Pharmaceuticals, aimed at the identification of novel dual ligands of the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR), as part of Esteve’s R&D activities to develop new, potent and safer analgesics.
The chemistry work was developed by Enantia’s Medicinal Chemistry team, led by Dr. Marina Virgili, in collaboration with Esteve Pharmaceuticals. Previous investigations carried out at Enantia established a suitable Lead, comprised of a spirocyclic morpholino-piperidine core identified using rational drug design strategies. Subsequent Lead Optimization has led to the discovery of EST73502, a clinical candidate undergoing Phase I clinical trials. The compound showed promising results in animal models with potent analgesic efficacy and improved safety compared to oxycodone.

Enantia offers a wide portfolio of drug discovery services for pharmaceutical and biotech companies, including the design and synthesis of new scaffolds and libraries of small molecules with potential biological activity, covering Hit finding, Hit-to-Lead and Lead Optimization programs. Additionally, Enantia can collaborate with Structure-Activity Relationship (SAR) and Drug Metabolism and Pharmacokinetics (DMPK) data analysis. Enantia has a long track record of collaborative research projects with the pharmaceutical industry, leading to more than 20 patent applications related to medicinal chemistry.
Besides the most common MedChem activities, Enantia can also contribute to the early stages of the drug development by preparing cold labelled compounds and metabolites of the candidates. Additionally, for later phases of development, our Solid State department counts with extensive expertise in identifying the best solid form of the candidate to be further developed.

You can read the full paper here.

Within this collaboration, a new robust and scalable synthetic route to obtain calcium acamprosate has been developed. The selective precipitation of calcium acamprosate as an easily filterable solid with 74–77% yield was achieved by the one-pot nucleophilic opening of 1,3-propanesultone with potassium acetamide, following by cation exchange with calcium ion at controlled pH.

In comparison with other procedures described in the literature and used previously, the newly developed and optimized methodology gives rise to a remarkably more efficient and direct synthesis of calcium acamprosate, avoiding the use of toxic chemicals and multistep synthesis.

This is a perfect example of how our process chemistry team can support our customers in designing and optimizing new routes of synthesis, leading to procedures that can be easily scaled up and used later at industrial scale. Furthermore, this type of projects can be complemented at Enantia by performing the carry-over of the impurities, and the characterization thereof.

You can read the full paper here.

Our CEO Dr. Joan Feixas will be attending the Future Cannabis Strategies Europe 2020, taking place in Royal Lancaster London on the 29^th and 30^th of January, 2020.

During the event, we will be discussing with key partners and customers about our Cannabinoids Cocrystal Platform, which enables the manufacturing of a wide range of cannabinoids, both from natural and synthetic origin.

As part of this platform, Enantia is already developing commercial batches of API grade cGMP Cannabidiol (CBD), along with minor cannabinoids such as Cannabidivarin (CBDV), Cannabigerol (CBG), Cannabichromene (CBC) and Cannabinol (CBN).

If you are interested in our very high-quality cannabinoids, or if you are looking for a cost-effective purification technology for your cannabis extracts, do not hesitate to contact us to organize a meeting.

The Journal of Medicinal Chemistry has recently published some of the results obtained in our Medicinal Chemistry collaboration with Esteve Pharmaceuticals, aimed at the identification of novel dual ligands of the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR), as part of Esteve’s RD activity to develop new, potent and safer analgesics.

The chemistry work, which was carried out by Enantia’s Medicinal Chemistry team led by Dr. Marina Virgili, started with the design of the spirocyclic morpholino-piperidine core using rational drug design strategies. The efficient synthetic approach developed, allowed then for the rapid preparation of analogues with diversification in several positions of the scaffold, rendering the promising Lead described in this paper. The subsequent Lead Optimization program led to the discovery of a clinical candidate, whose identification will be reported soon.

Enantia has a long track record in Medicinal Chemistry services to the pharmaceutical industry, with more than 20 patents related to this activity, which includes the design and synthesis of new scaffolds and libraries of small molecules with potential biological activity.

In addition to conventional MedChem activities such as Hit-to-Lead and Lead Optimization programs, Structure-Activity Relationship (SAR) and Drug Metabolism and Pharmacokinetics (DMPK) interpretation, Enantia can also collaborate in the early stages of the drug development process by preparing cold labelled compounds and metabolites of a given candidate, as well as by identifying its best solid form in our Solid State department.

You can read the full paper here.